Compare Ginkgo Bioworks Holdings Inc (DNA) vs Marathon Digital Holdings Inc (MARA) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

MARA stock trades at $9.71, down 6.27% on the day, reflecting a volatile trend. The technical outlook is bearish overall, with moving averages signaling a downtrend, though oscillators suggest potential for a short-term bounce. Fundamentally, the company reported a net loss of $1.31 billion in 2025 with a negative net income margin of -429.71%, despite a high gross margin of 76.71%. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -1.6 missing the expected 0.1666. Analyst sentiment is mixed, with a consensus price target of $13.25.

The outlook for MARA is challenged by persistent losses and negative profitability metrics, though low valuation ratios like a P/E of 3.37 may attract value investors. Key risks include execution challenges in achieving profitability, high cash burn from operations, and sensitivity to broader market sentiment. The stock's performance remains heavily influenced by news flow and sector momentum, requiring careful risk assessment for potential investors.